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Objectives. This multicenter study sought to evaluate the short- 
term efficacy and safety of prolonged, low dose, direct urokinase 
infusion in recanalization of chronically occluded saphenous vein 
bypass grafts in a large sample of patients, as well as to determine 
the 6-month patency rates for this procedure. 
Background. Patients with chronically occluded aortocoronary 
vein grafts and uncontrolled angina pectoris have limited options 
for therapy. Previous work has shown that chronically occluded 
vein grafts can be recanalized by thrombolysis. 
Methods. A coaxial infusion of urokinase (100,000 U/h) was 
given directly into occluded vein grafts in 107 patients. Balloon 
angioplasty was performed after lysis was achieved. Patients were 
discharged with warfarin and aspirin therapy. Six-month clinical 
follow-up data were obtained, and repeat angiography was encour- 
aged. 
Results. Initial patency was achieved in 74 patients (69%). 
Mean duration of infusion was 25.4 h, and mean urokinase dosage 
was 3.70 million U. Acute adverse events included acute myocar- 
dial infarction in 5 patients (5%), enzyme level elevation in 18 
(17%), emergency coronary artery bypass graft surgery in 4 (4%), 
stroke in 3 (3%) and death in 7 (6.5%). Recanalization was 
unsuccessful in all seven patients who died. Six-month follow-up 
angiograms were obtained for 40 patients (54%), 16 of whom 
maintained a patent graft (40%). Angina was present in 13 
patients with successful (22%) and 12 with unsuccessful (71%) 
recanalization at 6-month follow-up. 
Conclusions. Chronically occluded aortocoronary vein grafts 
can be recanalized in -70% of appropriately selected patients. 
Complications are similar to those observed with repeat opera- 
tions. Clinical follow-up shows an improvement in angina. This 
procedure is intended for patients with only one occluded vein 
graft. Strict adherence to the protocol will improve patency and 
reduce complications. 
(J Am CoU Cardiol 1996;27:60-6) 
Occlusion of aortocoronary b pass grafts is a major clinical 
problem facing patients and cardiologists. With as many as 
50% of patients developing an occluded graft within 10 years of 
operation, the number of affected patients is increasing (1). 
Options for treating these patients after onset of angina due to 
an occluded graft include medical therapy, angioplasty of the 
native vessel, repeat operation or recanalization of the oc- 
cluded graft. Medical therapy is usually the first approach to 
these patients but is frequently unsuccessful. Angioplasty of 
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the native vessel is not always possible because the native 
vessel is usually totally occluded. Direct balloon angioplasty in 
totally occluded vein grafts results in low initial success 
(<50%), high infarction (30%) and poor long-term patency 
rates (2). When a patient is not a candidate for repeat 
operation either because of age, patient refusal, poor anatomy 
or other complicating disease, he or she may benefit from 
recanalization f the occluded vein graft by thrombolysis. 
The present study extends previous research in this area 
using a combination ofrecanalization with prolonged, low dose 
infusion of urokinase directly into the occluded graft, followed 
by balloon angioplasty. The previous report (3) demonstrated 
this approach to be feasible but lacked good long-term follow- 
up. The Recanalization of Chronically Occluded Aortocoro- 
nary Saphenous Vein Bypass Grafts With Long-Term, Low 
Dose Direct Infusion of Urokinase Trial (ROBUST) (3) was a 
multicenter study of this technique with the study objectives of 
1) evaluating the etticacy and safety of prolonged, low dose 
direct infusion of urokinase into chronically occluded aorto- 
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0735-1097(95)00448-3 
JACC Vol. 27, No. 1 HARTMANN ET AL. 61 
January 1996:60 6 ROBUST 
coronary vein bypass grafts; and 2) determining the 6-month 
patency rate in these recanalized grafts. 
Methods 
Study patients. Patients <75 years of age with previous 
aortocoronary venous bypass grafts were candidates for enroll- 
ment in the trial. Inclusion criteria included 1) Canadian 
Cardiovascular Society class III or IV angina unresponsive to 
medical therapy; 2) presence of totally occluded end-to-side, 
nonsequential aortocoronary vein graft; 3) angiographic con- 
firmation of a single occluded saphenous vein graft considered 
to be the cause of the ischemia; 4) native vessel not amenable 
to balloon angioplasty; and 5) documentation f reversible 
ischemia on a thallium stress test (desirable but not mandatory). 
Exclusion criteria were 1) acute myocardial infarction within 
24 h; 2) contraindication to thrombolytic, aspirin or warfarin 
therapy; 3) angiographic evidence of a flush occlusion of the 
vein graft; 4) inability to advance aguide wire at least 1 cm into 
the occluded graft; 5) serum creatinine l vel >2.0 mg/dl; and 
6) history, of paroxysmal or chronic atrial fibrillation. 
The protocol was approved by the Human Investigation 
Review Committee at each participating clinical center, and all 
enrolled patients provided written informed consent. Because 
of the difficulty of identifying appropriate candidates with no 
other reasonable option for therapy and the desire to simply 
report the general efficacy and safety in a single group of 
patients undergoing this procedure, a convenience sample of 
100 consecutive patients meeting eligibility requirements was 
selected. Statistical tests of association or correlation were 
performed for various outcomes and baseline characteristics 
where appropriate. Tests of association were performed using 
Fisher exact ests for 2 x 2 tables and the Cochran-Mantel- 
Haenszel tests for nonzero correlation for 2 x N tables of 
ordinal categoric data. Two-sided 95% confidence intervals 
were constructed using the binomial distribution to estimate 
the true patency rates for all patients and various subsets of 
patients. Descriptive statistics, including percentages, mean 
values, standard eviations and interquartile ranges (25th to 
75th percentile) are reported for other characteristics where 
appropriate. 
Protocol, After initial angiography, an angiographic cathe- 
ter that would seat securely was placed into the orifice of the 
occluded graft. A 0.035-in. infusion wire was placed into the 
occlusion at least 2 cm after steering with a 0.014-in. guide 
wire. Urokinase was infused coaxially at 50,000 U/h proximally 
and distally (100,000 U/h total). Full anticoagulation with 
heparin was maintained throughout the infusion. Patients were 
then sent to the coronary care unit for monitoring. Follow-up 
angiography was performed at 4 to 8 h, 22 to 26 h or at the 
completion of infusion. Urokinase infusion was continued for 
at least 24 h and could be adjusted upward to 250,000 or 
360,000 U/h if no recanalization was observed on subsequent 
revisualizations. Balloon angioplasty was performed when 
thrombus was resolved or no further improvement was seen. 
No other devices, including atherectomy or stents, could be 
used. Initial therapy was judged to be successful when the 
target vein graft demonstrated patency, defined as Thrombol- 
ysis in Myocardial Infarction trial (TIMI) grade 2 or 3 flow 
after thrombolytic nfusion and balloon angioplasty if neces- 
sary, as determined by subsequent independent review of the 
cineangiographic f lms conducted at the Midwest Heart Re- 
search Foundation. 
Laboratory measurements included fibrinogen and plas- 
minogen levels, partial thromboplastin time, hemoglobin, he- 
matocrit, platelet count and cardiac enzyme levels every 4 h 
during the infusion. 
Heparin was continued after sheath removal until patients 
achieved full anticoagulation with warfarin. Patients were 
discharged with aspirin and warfarin therapy for at least 6 
months. Six-month clinical follow-up data for all patients were 
obtained, and 6-month angiography was encouraged for all 
patients with successful recanalization. 
Baseline cineangiograms were reviewed by surgeons at the 
participating institutions and at the coordinating center. The 
surgeons had no knowledge of clinical history and physical data 
and were asked to assess urgical difficulty on the basis of film 
review only. Cases were ranked using the following "distal 
runoff" scoring classification, which evaluated surgical diffi- 
culty by analyzing the size and degree of disease of the distal 
vessel as well as the amount of myocardium atrisk: Class A = 
technically easy; moderate amount of myocardium at risk; 
good results expected. Class B = technically easy; small 
amount of myocardium atrisk; one-vessel disease only; balloon 
angioplasty might be better. Class C = difficult but technically 
operable; marginal benefit due to the small amount of myo- 
cardium at risk. Class D = difficult; would not want to operate 
unless necessary; small distal vessel; good result not expected. 
Class E = inoperable. 
Results 
Initial outcome. One hundred seven patients were enrolled 
at the seven centers. Their baseline clinical characteristics are 
shown in Table 1. The age of graft occlusion was reported from 
the time of sudden onset of new symptoms, udden change in 
stable symptoms or confirmation by angiography if available. 
Seventy patients were enrolled within 1 month of occlusion, 11 
within 1 to 2 months, 7within 2 to 3 months, 6within 3 to 6 
months and only 1 after 6 months. In 12 patients, the duration 
of occlusion could not be determined. 
The initial recanalization rate for the group as a whole was 
69% (95% confidence interval [CI] 59% to 78%). Patients 
were classified into two groups: 72 patients who were protocol 
compliant and 35 with protocol violations. The most frequent 
protocol violation was enrollment of patients with more than 
one occluded graft (n = 17) followed by inadequate urokinase 
dosage or use of the transluminal extraction catheter atherec- 
tomy device (n = 5 each); native vessel amenable to angio- 
plasty; percutaneous transluminal coronary angioplasty before 
initiation of lysis or sequential grafts (n = 3 each); no coaxial 
infusion; inadequate infusion wire positioning or target graft 
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Table 1. Baseline Clinical Characteristics of 107 Patients 
Undergoing the Recanalization Protocol 
Mean age (yr) 61 
Male 79% 
Caucasian 97% 
Smoker 60% 
Family Hx of CAD 56% 
CHF 8% 
Hypertension 51% 
Diabetes 20% 
Exercise angina 65% 
Rest angina 68% 
Previous AMI 72% 
Previous PTCA target graft 13% 
Repeat CABG 15% 
AMI = acute myocardial infarction; CABG - coronary artery bypass graft 
surgery; CAD = coronary artery disease; CHF - congestive heart failure; Hx = 
history; PTCA = percutaneous transluminal coronary angioplasty. 
not 100% occluded (n = 2 each); and chronic atrial fibrillation 
or excess dosage (n = 1 each). Some patients had more than 
one protocol violation (Table 2). Success rates were higher in 
protocol-compliant patients (78%, 95% CI 66% to 87%) than 
in those with protocol violations (51%, 95% CI 34% to 69%) 
(p = 0.008) (Table 3). Balloon angioplasty was performed in 
88% of recanalized vessels. Success rate by surgical classifica- 
tion is shown in Figure 1. Success rates tended to be smaller as 
surgical ditficulty increased (p = 0.017 for correlation), but 
even the class D group had a 59% success rate (95% CI 44% 
to 90%). The initial success rate was not greatly influenced by 
the age of the graft (p = 0.884 for correlation) (Fig. 2). 
Immediate success was also not influenced by duration of 
occlusion (p = 0.394 for correlation) (Fig. 3), but there was 
only one patient enrolled with a graft occluded >6 months. 
The initial success rate was 100% (95% CI 92% to 100%) in 
patients who achieved TIMI flow grade 2 or 3 by thrombolysis 
alone (Fig. 4). Only 33 patients (15%, 95% CI 5% to 32%) with 
TIMI flow grade 0 after thrombolysis had successful recanali- 
zation by attempted angioplasty (p < 0.001 for correlation of 
success rate with TIMI flow grade) (Fig. 4). 
Table 3. Initial Recanalization Efficacy in 107 Patients 
Protocol Protocol 
Compliant Violation Total 
Recanalization (n = 72) (n = 35) (n = 107) 
Successful 56 (78%) 18 (51%) 74 (69%) 
Unsuccessful 16 (22%) 17 (49%) 33 (31%) 
Data presented are number (%) of patients. 
Mean urokinase infusion dosage and duration were similar 
for the two groups (successful vs. unsuccessful). In patients 
with successful recanalization, mean urokinase infusion dosage 
was 3.63 million U (interquartile range [IQR] [2.21, 4.73]), and 
mean urokinase infusion duration was 25.7 h (IQR = [19.67, 
29.88]). In patients with unsuccessful recanalization, mean 
urokinase infusion dosage was 3.86 million U (IQR [2.02, 
5.17]), and mean urokinase infusion duration was 24.6 h (IQR 
[19.16, 31.57]). Mean baseline fibrinogen levels were not 
significantly different between patients with successful and 
unsuccessful recanalization. Significant systemic fibrinogenoly- 
sis did not occur at the dose and duration of urokinase used in 
this trial. Mean nadir fibrinogen level was similar for the two 
groups: 257.1 (_+89.8) in patients with successful and 239.7 
(_+100.1) in those with unsuccessful recanalization (p = 0.380). 
Complication rates are shown in Table 4 and were higher in 
patients with unsuccessful recanalization and in those with 
protocol violations. Q wave myocardial infarction occurred in 
five patients (5%) (three protocol compliant [4%], two with 
protocol violations [6%], p = 0.824). Enzyme release was the 
most frequent complication (18 patients [17%]). Emergent 
coronary artery bypass graft surgery was necessary in four 
patients (4%) (one protocol compliant [3%], two with protocol 
violations [6%], p = 0.596). Stroke occurred in three patients 
(3%) and in-hospital death in seven (6.5%) (one protocol 
compliant [1%], six with protocol violations [17%], p = 0.005). 
Clinically significant hematomas occurred in 4 patients (4%) 
and retroperitoneal bleeding in 2 (2%). Blood transfusions 
were given to 20 patients (19%) whose mean nadir hemoglobin 
was 9 g/dl. 
Table 2. Protocol Violations in 107 Enrolled Patients 
No. of 
Type of Violation Patients 
Multiple occluded grafts 17 
Premature infusion termination 5 
Transluminal extraction catheterization 5 
Native artery PTCA 3 
Sequential graft 3 T 
PTCA before thrombolysis 3 E 
No coaxial infusion 2 
Inadequate infusion wire positioning 2 N 
Target graft not occluded 2 C 
Urokinase dose exceeded 1 
Chronic atrial fibrillation 1 Y 
PTCA = percutaneous transluminal coronary angioplasty. 
Figure 1. Success rate by surgical c assification evaluating distal vessel 
runoff. See text for explanation f surgical classification. 
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Figure 2. Initial success rate according toage of saphenous vein graft. 
In-hospital death. Table 5 reflects the time of death from 
enrollment, cause of death and protocol violation, if present. 
All seven patients who died in hospital were in surgical class D 
or E. Only two of the deaths were considered procedure 
related. In the first patient, with a previous history of a 
transient ischemic attack, the urokinase infusion had exceeded 
the 8-million U cutoff dose, and this patient died of intracere- 
bral bleeding 4 h after infusion termination. The second 
patient was enrolled within 24 h of a non-Q wave myocardial 
infarction and died of a ruptured ventricle during the infusion. 
Six of the seven deaths occurred in the group with protocol 
violations (p = 0.005, compliant versus noncompliant groups 
for death rate). None of the seven patients had a successfully 
recanalized vessel (p < 0.001). The one patient who did not 
have a protocol violation died of refractory ventricular fibril- 
lation and had an ejection fraction of 15%. Four of the seven 
patients who died had more than one occluded graft or a 
sequential target graft. 
Long-term outcome. Angiographic follow-up was obtained 
in 40 (54%) of 74 patients with successful recanalization. The 
remaining 34 patients were either physically unable to undergo 
angiography or refused restudy. Forty percent (95% CI 25% to 
57%) of these grafts were patent on follow-up. Sixty-seven 
percent of patients who achieved TIMI grade 3 flow after 
Figure 3. Initial success rate according toduration of graft occlusion 
for the 95 patients inwhom the duration could be determined. 
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Figure 4. Initial success rate as influenced by Thrombolysis in Myo- 
cardial Infarction (TIMI) perfusion grade after thrombolysis but 
before balloon angioplasty. 
thrombolysis but before balloon angioplasty had a patent graft 
on 6-month angiography (95% CI 35% to 90%) compared with 
29% of patients (95% CI 13% to 49%) with TIMI grade 0 to 
2 flow (Fig. 5). Six-month patency was not adversely influenced 
by age of the graft (p = 0.849) (Fig. 6). Thirteen patients with 
a patent graft (82%) and 22 with an occluded graft (91%) were 
taking both aspirin and warfarin. 
Clinical follow-up at 6 months (Table 6) was obtained in 89 
(87%) of 102 patients discharged from the hospital and showed 
that angina was present in 13 patients in the successful group 
(22%) versus 12 in the unsuccessful group (71%) (p < 0.001). 
Myocardial infarction occurred in one patient in the successful 
group (2%) versus none in the unsuccessful group (p = 1.000). 
Repeat balloon angioplasty or coronary artery bypass urgery 
was performed infour patients in the successful group and one 
in the unsuccessful group (both 6%). Two patients (3%) died 
suddenly in the successful group during the 6-month follow-up 
interval (p = 1.000). 
Discuss ion  
Overview. Aortocoronary vein graft occlusion is a common 
problem facing cardiologists today. Occlusions of up to 20% 
have been reported within the first year after bypass urgery, 
and at least 50% of patients have at least one graft occluded by 
10 years (1). Any procedure that can prolong or avoid the 
necessity for another operation would be of great benefit to the 
patient. 
Previous approaches to occluded aortocoronary vein grafts. 
Direct angioplasty of totally occluded vein grafts has been 
fraught with dflficulty, de Feyter et al. (2) reported the results 
of direct balloon angioplasty in 15 patients with total occlu- 
sions of 3 to 6 months in duration. Initial clinical success was 
achieved in seven patients (47%) with five procedural myocar- 
dial infarctions (30%). Only one patient maintained a patent 
vessel at follow-up. This led de Feyter et al. (2) to state what 
has since become the consensus on direct angioplasty intotally 
occluded vein grafts: it is "a challenge that should be resisted." 
A recent report by Kahn et al. (4), using direct angioplasty 
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Table 4. Initial Adverse Events 
Successful Unsuccessful Protocol Protocol 
Recanalization Recanalization Compliant Violation Total 
Q wave MI 1% (1) 12% (4) 4% (3) 6% (2) 5% (5) 
Enzyme levation 16% (12) 18% (6) 15% (11) 20% (7) 17% (18) 
Emergent CABG 1% (1) 9% (3) 3% (2) 6% (2) 4% (4) 
Stroke 0% (1) 9% (3) 3% (2) 3% (1) 3% (3) 
Death 0% (0) 21% (7) 1% (1) 17% (6) 6.5% (7) 
Data presented are percent (number) ofpatients. CABG = coronary artery bypass graft surgery; MI = myocardial 
infarction. 
as the major mode of recanalization, demonstrated a different 
outcome with a 73% patency rate in 83 patients with totally 
occluded vein grafts, with short-term (<1 h) thrombolysis in 
only 13% of the patients. However, only 57% of their patients 
had a proximal occlusion compared with 100% in the present 
report, and only 55% of their patients presented with intragraft 
thrombus. Twelve percent of their patients' graft occlusions 
could not be crossed compared with >90% in our patients. 
Therefore, this group represents a different patient cohort 
from that described in the present report. 
Complications with older vein grafts. Totally occluded 
aortocoronary vein grafts are a very different disease entity 
from that of nonoccluded, stenotic vein grafts. The goal of the 
procedure described in the present study is to reduce the 
thrombus burden in a totally occluded graft and, as such, to 
convert it to a nonoccluded graft in which angioplasty can be 
performed with a lower complication rate. Platko et al. (5) 
reported results of primary angioplasty in 101 nonoccluded 
vein grafts and found that all the complications (15%) oc- 
curred in vein grafts >3 years old. Angioplasty in nonoccluded 
vein grafts >3 years old is associated with a 12.5% acute 
myocardial infarction rate, 6% emergency coronary artery 
bypass graft surgery rate and 4% mortality rate (5). Our 
complication rates for the protocol-compliant patients of 4% 
transmural infarction, 3% emergency coronary artery bypass 
Table 5. In-Hospital Cause of Death for Seven Patients 
Cause of Death Protocol Violation 
Days 
After 
Enrollment 
Intracranial hemorrhage* Urokinase dose 2 
maximum exceeded 
Ruptured ventricle* Multiple SVG 2 
occluded 
Refractory ventricular fibrillation None 28 
Electrical mechanical Sequential grafts l 
dissociation 
Post-CABG ARDS Multiple SVG 21 
occluded 
Refractory ventricular fibrillation Native vessel amenable 9 
to PTCA 
Refractory ventricular fibrillation Multiple SVG 8 
occluded 
*Procedure lated. ARDS = adult respiratory distress syndrome; SVG = 
saphenous vein graft; other abbreviations as in Table 1. 
graft surgery and 1% mortality compare favorably with other 
studies in which procedures were performed in older, nonoc- 
cluded vein grafts. 
Repeat operations. Repeat aortocoronary bypass opera- 
tions are associated with mortality rates that range from 3% to 
12% (average 4.6%) (6-8), and perioperative myocardial 
infarction occurs in 8% to 18% (average 9.8%). Compared 
with a mortality rate for primary operations of 1% and a 
perioperative myocardial infarction rate of 0.6% (8), second 
operations are the last resort for patients with refractory 
unstable angina with only one occluded vein graft. 
Initial pateney. The present study confirms earlier work on 
this experimental procedure (3). A patency rate of -70% can 
be expected for appropriately selected patients. Initial and 
6-month patency is not related to the age of the graft or 
duration of occlusion and is improved when TIMI flow grade 3 
is achieved by lysis alone. TIMI flow grade 2 influenced initial 
but not long-term patency. The present study confirms previ- 
ous reports (2) that state that angioplasty of totally occluded 
vein grafts not recanalized with thrombolysis be avoided. 
The dose of urokinase used in the present rial was exper- 
imental and was derived from experience with this dose in 
totally occluded peripheral arteries. The mean urokinase dose 
and duration of infusion were similar in both successfully and 
unsuccessfully treated patients, suggesting an anatomic reason 
for the lack of success. 
Embolization. Gruentzig originally warned about emboli- 
zation during angioplasty of aortocoronary vein grafts in 1983 
Figure 5. Six-month angiographic patency rate according to Throm- 
bolysis in Myocardial Infarction (TIMI) perfusion grade after throm- 
bolysis but before balloon angioplasty. 
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Figure 6. Six-month angiographic patency rate according to age of 
saphenous vein graft. 
(9). Embolization most likely accounted for the enzyme level 
elevations observed in 18 of our patients (17%). The Q wave 
myocardial infarction rate of 5% (protocol-compliant group 
4%, protocol violation group 6%) is similar to that reported for 
angioplasty of nonoccluded grafts (5). According to protocol, 
the urokinase dosage was doubled when chest pain and 
electrocardiographic evidence of infarction were present, 
which frequently reduced the duration of pain and dissolved 
the distal emboli. Angioplasty at this stage would not result in 
improvement but only further embolization, and operation is 
usually not an option because of the extent of the distal 
embolization. Once distal embolization occurs, the only rea- 
sonable option is to attempt to increase the speed of lysis. 
Embolization remains a major problem with the present 
procedure. It is likely that the Q wave infarctions and enzyme 
level elevations were caused by thrombotic or atherosclerotic 
emboli. Enzyme level elevations occurred in 18 patients (17%) 
but resulted in a Q wave myocardial infarction in only 5 (5%). 
Increasing the dose of urokinase appeared to dissolve the 
distal emboli n the majority of patients when it occurred. The 
presence of more than one occluded vein graft was an exclu- 
sion criterion because of concern for distal embolization, which 
would most likely disturb the sensitive collateral system that 
appears to be present in these patients. 
Six-month follow-up. Six-month patency remains a di- 
lemma. Fifty-four percent of our patients returned for 6-month 
angiography, and 40% of those studied showed patent vessels. 
Table 6. Six-Month Clinical Follow-Up 
Successful Unsuccessful 
Recanalization Recanalization Total 
Angina 22% (13) 71% (12) 33% (25) 
AMI 2% (1) 0% (0) 1% (1) 
CHF 3% (2) 0% (0) 2% (2) 
Stroke 0% (0) 0% (0) 0% (0) 
PTCA 3%, (2) 6% (1) 4% (3) 
Repeat CABG 3% (2) 0% (0) 2% (2) 
Death 3% (2) 0% (0) 2% (2) 
Data presented are percent (number) ofpatients. AMI = acute myocardial 
infarction; other abbreviations as in Table 1. 
Restenosis rates in 12 other studies of angioplasty in nonoc- 
cluded vein grafts averaged 42% (8-19). Platko et al. (5) 
reported an 83% restenosis rate (54% restudied) at 14 months 
in vein grafts >3 years old. Long-term follow-up revealed that 
those patients were at the end-stage of coronary disease 
because their 5-year event-free survival rate was only 36%, 
with a 14-month mortality rate of 10.5%. 
Clinical follow-up of our patients at 6 months howed that 
patients with successful recanalization have more relief of 
angina (22% vs. 71%) but are at greater isk for recurrent 
events (acute myocardial infarction 2%, balloon angioplasty 
3%, coronary artery bypass urgery 3%, death 3%). 
In the design of the present trial, it was anticipated that the 
addition of aspirin and warfarin would maximize patency, but 
this did not occur. At the time that this trial was initiated, 
newer technologies were not approved. In addition, long-term 
patency rates for atherectomy and stents are not known. 
However, a prolonged thrombolytic nfusion will prepare an 
occluded vein graft for atherectomy or stent implantation. 
Conclusions. Aortocoronary vein graft occlusion remains a
major clinical challenge. The approach described here offers 
one method of preserving the life of some occluded vein grafts. 
Initial success rates can exceed 70% in appropriately selected 
patients. 
Complications of prolonged thrombolysis can be reduced 
by strict adherence to defined criteria. The age of the graft 
does not appear to affect initial or 6-month patency, nor does 
the duration of graft occlusion (up to 6 months). 
The present procedure should be used in patients with only 
one occluded vein graft. Achievement ofTIMI flow grade 3 by 
lysis before angioplasty improves initial and 6-month patency. 
Because initial success was extremely ow in patients with unsuc- 
cessful pretreatment (TIMI flow grade 0) with urokinase, further 
attempts at recanalization should be avoided. The addition of 
aspirin and warfarin may not have an effect on 6-month patency. 
These patients with chronically occluded saphenous vein 
bypass grafts are at the end-stage of their disease process, as 
evidenced by the higher mortality rate in the patients with 
unsuccessful recanalization. The procedure reported here is 
safe and effective when limited to the patients defined in our 
protocol. However, it should be reserved for those patients 
with refractory angina and no other reasonable option for 
therapy. Extending this procedure to other patients may result 
in increased morbidity and mortality. This procedure can 
increase options for therapy in a high risk group of patients 
and prepare an occluded vein graft for new technologies (i.e., 
stents) that may improve long-term patency and outcome. 
Appendix 
Participating Investigators and Institutions in the 
ROBUST Study 
Midwest Heart Research Foundation: Peter M. Kerwin, MD (Co- 
Investigator), Stephen M. Bowley, MD (Co-Investigator), Julie S. Gur- 
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gone (Study Coordinator), Joanne Cuny (Stud), Coordinator). William 
Beaumont Hospital: Ann Margulis, RN (Study Coordinator), Debbie 
Davey, RN (Study Coordinator), Denise Mason, RN (Study Coordina- 
tor). The Cleveland Clinic Foundation: Kevin Vaska, MD (Co- 
Investigator), Sue Deluca (Study Coordinator), Michelle Webb (Study 
Coordinator). University of Florida Medical Center: Theodore A. 
Bass, MD (Co-Investigator), Gail Rohman, RN (Study Coordinator), 
Paula Downing, RN (Study Coordinator). Abbott Laboratories Throm- 
bolytic Venture: Arthur A. Sasahara (Director), Esther Villiard (Clin- 
ical Research Associate), Kathryn Hart (Clinical Research Associate). 
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